A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors

Clinical trial NCT04093466 · RECRUITING

Trial details

NCT number: NCT04093466
Sponsor: Beijing Konruns Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor

Start date: 2020-04-27
Primary completion: 2025-10-01
Enrollment: 126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.